TTLL10 Inhibitors
TTLL10 inhibitors encompass a diverse range of chemical compounds that reduce the functional activity of TTLL10 by interacting with various components of the microtubule dynamics and modification pathways. Histamine, by saturating post-translational modification pathways during inflammation, can lead to a decreased need for TTLL10's enzymatic activity on tubulin. Similarly, nicotine's modulation of neuronal signaling could diminish tubulin modification demand, thereby reducing TTLL10 activity. Methotrexate and Hydroxyurea, by inhibiting enzymes crucial for DNA synthesis, reduce cell proliferation and thus the requirement for microtubule modifications, indirectly affecting TTLL10 function. Colchicine, Vincristine, Vinblastine, and Eribulin interact directly with tubulin, inhibiting its polymerization or assembly into microtubules, and thereby decreasing the substrate availability for TTLL10 to exert its tubulin-modifying effects. On the other hand,Taxol's stabilization of microtubules limits the need for further modification by TTLL10, as does Nocodazole's disruption of microtubule dynamics.
Moreover, Forskolin, by increasing cAMP levels and activating PKA, may lead to a competitive environment for tubulin modification, indirectly limiting TTLL10's activity. Lithium chloride's inhibition of GSK-3 alters MAP phosphorylation, which could impede TTLL10's access to tubulin substrates by modifying the microtubule network. The actions of these inhibitors collectively result in a reduction of TTLL10 activity, as the enzyme's functional role in the post-translational modification of tubulin is undermined by the altered state of microtubule dynamics and availability. The efficacy of these compounds in diminishing TTLL10 activity underscores the interdependence between microtubule dynamics, cell cycle processes, and post-translational modification systems, highlighting the complexity of targeting specific proteins within highly interconnected cellular pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine, through its role in the inflammatory response, can trigger pathways that lead to the post-translational modification of proteins. Given that TTLL10 is involved in the post-translational modification of tubulin, increased histamine levels could indirectly lead to a decrease in TTLL10 activity by saturating modification pathways. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate acts by inhibiting dihydrofolate reductase, leading to reduced purine synthesis and subsequent downregulation of rapidly dividing cells. This decrease in cellular turnover can lead to reduced TTLL10 activity because fewer microtubules would require modification in a slower cell cycle. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Hydroxyurea inhibits ribonucleotide reductase, leading to decreased DNA synthesis. This could indirectly diminish TTLL10 activity by reducing the need for microtubule modifications in cells with decreased proliferation. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin, inhibiting its polymerization into microtubules. This direct interaction with tubulin could decrease the functional activity of TTLL10 by preventing its access to the tubulin substrates. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Taxol stabilizes microtubules and prevents their disassembly. By locking microtubules in a stable state, the need for further modification by TTLL10 could be diminished. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule dynamics by inhibiting polymerization. This could lead to decreased TTLL10 activity as the dynamic state of microtubules, which requires ongoing modification, is altered. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin elevates cAMP levels and activates PKA, which can phosphorylate various proteins. Increased phosphorylation activity could potentially reduce the availability of TTLL10's tubulin substrates due to competitive modification processes. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3), which could alter microtubule-associated protein (MAP) phosphorylation and thus indirectly reduce TTLL10's ability to modify tubulin by changing the microtubule landscape. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Vinblastine binds to tubulin and inhibits microtubule assembly. Reduced microtubule polymerization could lead to a diminished need for TTLL10's tubulin-modifying activity. | ||||||
Eribulin | 253128-41-5 | sc-507547 | 5 mg | $865.00 | ||
Eribulin inhibits the growth phase of microtubule dynamics, leading to a decrease in available tubulin for modification. This could indirectly reduce the functional activity of TTLL10 by limiting its substrate pool. | ||||||